Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Posterior iris-claw aphakic intraocular lens implantation in eyes without adequate capsule support

Poster Details

First Author: F. Abdulaliyeva AZERBAIJAN

Co Author(s):    A. Akhmadova   A. Sultanova   A. Mamedbeyli              

Abstract Details


To evaluate the indications, visual outcomes and intraocular stability and safety of posterior aphakic iris-claw intraocular lenses (IOLs).


National Ophtalmology Centre after named academic Z.Aliyeva, Baku, Azerbaijan


Sixteen eyes of 16 patients without adequate capsule support had posterior chamber iris-claw aphakic IOL implantation (Artisan, Ophthec BV, Groningen, The Netherlands). Primary outcome measurements included visual acuity (6 m Snellen charts), central endothelium cell count (ECC) and intraocular position of the IOL assessed with anterior segment optical coherence tomography (OCT, Zeyss) and with Pentacam HR (Oculus). Mean age was 54.55 years (range, 35-98 years). Mean follow-up was 41.8 months (SD 23.63).


The IOLs were inserted during primary lens surgery in 3 eyes (18,75%), during an IOL exchange procedure for dislocated posterior chamber IOLs in 6 eyes (37,5%), and as a secondary procedure in 7 aphakic eyes (43,75%). The final mean corrected distance visual acuity (CDVA) (0.38±0.31 [SD] logMAR) was significantly better than preoperatively (0.65±0.58 logMAR) (P<0.05). Mean preoperative ECC was 2117.47 (SD 793.33) cells/mm2 and decrease over the years ( p=0.05). The anterior chamber depth was 4.24 mm. Postoperative complications included slight temporary pupil ovalization in 4 eyes (25%), cystoid macular edema in 3 eyes (18.75%) and transient postoperative hypotony in 1 eye (6.25%).


The posterior implantation technique of aphakic iris-claw IOL provided good visual outcomes with a favorable complication rate and can be used as a reasonable alternative for a wide range of indications in eyes without adequate capsular support.

Financial Disclosure:


Back to Poster listing